Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: Does the MPA level matter?

American Journal of Transplantation

Volumn 4, Issue 9, 2004, Pages 1495-1500

  Gajarski, Robert J ^a   Crowley, Dennis C ^a   Zamberlan, Mary C ^a   Lake, Kathleen D ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Division of Nephrology   (United States)

Author keywords

Mycophenolate mofetil; Pediatric; Pharmacokinetics

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; DRUG METABOLITE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; CONTINGENT VALUATION; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE CONCENTRATION CORRELATION; DRUG MONITORING; FEMALE; GRAFT REJECTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MALE; PRIORITY JOURNAL; SCORING SYSTEM;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MEDICAL RECORDS; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES;

EID: 4344645217     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00534.x     Document Type: Conference Paper

References (20)

1. Boucek MM, Edwards LB, Berkeley MK et al. J Heart Lung Transplant 2002; 21: 827-840.
2. Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996; 51: 278-298.
3. Langman LJ, LeGatt DF, Yatscoff RW et al. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity. Clin Chem 1995; 41: 295-299.
4. Meiser BM, Pfeiffer M, Schmidt D et al. The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough levels. Transplantation Proc 1999; 31: 84-87.
5. Yamani MH, Starling RC, Goormastic M et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation 2000; 69: 2326-2330.
6. Mourad M, Wallemacq P, Konig J et al. Therapeutic monitoring of Mycophenolate Mofetil on organ transplant recipients - is it necessary? Clin Pharmacokinet 2000; 41: 319-327.
7. Muller MM, Vogl M, Griesmacher A. Mycophenolic acid monitoring in HTX patients: a preliminary report. Therapie 1997; 52: 341-344.
8. Zucker K, Rosen A, Tsaroucha A et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and autologous in vitro findings. Transplant Immunol 1997; 5: 225-232.
9. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monitor 1999; 21: 35-43.
10. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of Tacrolimus and Cyclosporine on the pharmacokinetics of Mycophenolic Acid. Ther Drug Monit 2001; 23: 119-128.
11. Smak Gregoor PJH, De Sevaux RGL, Hene RJ et al. Effects of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999; 68: 1603-1606.
12. Cattaneo D, Perico N, Gaspari F et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62: 1060-1067.
13. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunsuppression. Pediatr Nephrol 2000; 14: 100-104.
14. Fernandez de Gatta M, Santos-Buelga D, Dominguez-Gil A, Garcia MJ. Immunosuppressive therapy for paediatric transplant patients. Clin Pharmacokinet 2002; 41: 115-135.
15. Dipchand AI, Pietra B, McCrindle BW, Rosebrook-Bicknell H, Boucek M. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil. J Heart Lung Transplant 2001; 20: 1035-1043.
16. Pawinski T, Hale M, Korecka M et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002; 48: 1497-1504.
17. Schutz E, Armstrong VW, Shipkova M et al. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. Transplant Proc 1998; 30: 1182-1184.
18. Shaw LM, Holt DW, Oellerich M et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23: 305-315.
19. Vogl M, Weigel G, Seebacher G et al. Evaluation of the EMIT mycophenolic acid assay from Dade Behring. Ther Drug Monitor 1999; 21: 638-643.
20. Pirsch J, Bekersky I, Vinceti F et al. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharm 2000; 40: 527-532.